ECMO Devices Market Outlook: Regional Insights

ECMO Devices Market Outlook: Regional Insights and Market Expansion

Global Extracorporeal Membrane Oxygenation (ECMO) Devices Market: Growth Trends and Key Developments

The global market for extracorporeal membrane oxygenation (ECMO) devices is anticipated to expand at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2030. The increasing adoption of ECMO systems is attributed to the growing prevalence of chronic cardiac and respiratory disorders, technological advancements improving patient outcomes, and the rising demand for ECMO machines. Additionally, market expansion is driven by the introduction of innovative technologies, an increasing burden of heart and lung diseases, and a surge in regulatory approvals and product launches.

Notable Developments in the ECMO Market

August 2022: AirECMO, Inc., a subsidiary of Keystone Perfusion Services, partnered with REVA, a leading air ambulance provider, to enhance global ECMO transportation services.
July 2022: Inspira™ Technologies launched the Liby System, an advanced ECMO-based life support solution for patients with severe cardiac and pulmonary failure.
April 2020: The U.S. Food and Drug Administration (FDA) issued guidelines to expand the availability of ECMO devices during the COVID-19 public health emergency.
April 2020: Abiomed acquired Breethe, a company specializing in ECMO systems, to enhance its portfolio and better address respiratory failure and cardiogenic shock associated with ARDS, H1N1, SARS, and COVID-19.

Market Dynamics Fueling ECMO Adoption

A significant factor driving the ECMO market is the rising incidence of cardiovascular and respiratory diseases. ECMO systems play a critical role in providing prolonged extracorporeal circulation and gas exchange for patients requiring extended cardiopulmonary support.

Ischemic heart disease (IHD), also known as coronary artery disease (CAD), remains a leading global cause of mortality. A 2020 epidemiological study reported that approximately 126 million people (1.72% of the global population) suffer from IHD annually. Many patients undergoing cardiovascular surgeries require circulatory support, increasing ECMO demand.

According to the British Heart Foundation (2023), an estimated 620 million individuals worldwide are living with heart and circulatory diseases. Meanwhile, the World Health Organization (WHO) reported that cardiovascular diseases caused 17.9 million deaths in 2021, accounting for 31% of global fatalities. This number is projected to reach 23.6 million by 2030.

Market Segmentation of ECMO Devices

The ECMO devices market is segmented based on machine modality, patient type, application, and geography:

By Machine Modality: Veno-Arterial, Veno-Venous, and Arterio-Venous
By Patient Type: Pediatric and Adult
By Application: Respiratory, Cardiac, and Others
By Geography: North America, Europe, Asia-Pacific, and Rest of the World

The respiratory application segment is expected to hold a significant market share due to the high incidence of respiratory disorders. Asthma, a major non-communicable disease, affected approximately 262 million people in 2019 and resulted in 250,000 deaths, according to the WHO.

ECMO also played a vital role in managing severe COVID-19 cases. The Extracorporeal Life Support Organization (ELSO) reported that ECMO was instrumental in improving survival rates for critically ill COVID-19 patients when conventional ventilation methods were ineffective, with a survival rate of approximately 55% among those placed on ECMO.

North America Leads the ECMO Market

North America is projected to maintain a dominant position in the ECMO market, driven by a rising prevalence of cardiovascular and pulmonary diseases, an aging population, and continuous technological advancements.

The COVID-19 pandemic accelerated demand for compact cardiopulmonary bypass systems. In October 2020, Abiomed secured FDA 510(k) clearance for its Breethe OXY-1 system, further propelling the ECMO market in the U.S.

Data from the Centers for Disease Control and Prevention (CDC) underscore the increasing demand for ECMO:

Over 795,000 strokes occur annually in the U.S.
Approximately 200,000 coronary artery bypass graft procedures are performed each year, making it one of the most common cardiac surgeries.

To address this growing need, the FDA granted 510(k) clearance to Abiomed’s Breethe OXY-1 System in October 2020.

Leading Companies in the ECMO Devices Market

Key players shaping the ECMO market include:

Getinge Group
Medtronic
LivaNova PLC
XENIOS AG
Terumo Corporation
MicroPort Scientific Corporation
NIPRO Corporation
OriGen Biomedical, Inc.
EUROSETS S.r.l.
ALung Technologies, Inc.
Medos Medizintechnik AG
Abiomed
Novalung
Sorin
Thoratec Corporation
MAQUET Holding B.V. & Co. KG
Tianjin Medical
SHANDONG WEGO NEW LIFE MEDICAL DEVICES CO., LTD.

Future Outlook

The ECMO devices market is set for steady growth, driven by increasing cases of cardiovascular and respiratory diseases, continuous technological advancements, and the widespread adoption of ECMO systems globally. North America remains the market leader, supported by a well-established healthcare infrastructure and a rise in product approvals. As innovation accelerates and new players enter the market, the ECMO industry is expected to expand significantly in the coming years.

Related Reports by DelveInsight:

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Info:

Kritika Rehani

krehani@delveinsight.com

info@delveinsight.com

www.delveinsight.com

+14699457679